The evolving role of antibody–drug conjugates in the treatment of urothelial carcinoma

Listen to a genitourinary cancer expert outline the use of antibody–drug conjugates in the treatment of urothelial carcinoma, including their place in current treatment guidelines, clinical trial data and the management of possible adverse events. The expert Dr Cora Sternberg, Weill Cornell Medicine, New York, NY, USA This touchPODCAST is for HCPs only.  This activity is funded by an unrestricted independent medical education grant from Gilead Sciences and Seagen. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/antibody-drug-conjugates-in-urothelial-carcinoma/